Prior studies report that 9-27% of persons receiving a hematopoietic cell transplant develop arrhythmias, but the effect on outcomes is largely unknown. We reviewed data from 1177 consecutive patients ⩾ 40 years old receiving a hematopoietic cell transplant at one center during 1999-2009. Transplant indication was predominately leukemia, lymphoma and multiple myeloma. Overall, 104 patients were found to have clinically significant arrhythmia: 43 before and 61 after transplant. Post-transplant arrhythmias were most frequently atrial fibrillation (N = 30), atrial flutter (N = 7) and supraventricular tachycardia (N = 11). Subjects with an arrhythmia post transplant were more likely to have longer median hospital stays (32 days vs 23, P = o 0.001), a greater probability of an intensive care unit admission (52% vs 7%; P o0.001), greater probability of in-hospital deaths (28% vs 3%, P o 0.001), and greater probability of death within 1 year of transplant (41% vs 15%; P o0.001) compared with patients without arrhythmia at any time. In a multivariate model including age at transplant, diagnosis, history of pretransplant arrhythmia, and transplant-related variables, post-transplant arrhythmia was associated with a greater risk for death within a year of transplant (odds ratio 3.5, 95% confidence interval: 2.1, 5.9; P o0.001). Our data suggest that arrhythmias after transplants are associated with significant morbidity and mortality. A prospective study of arrhythmia in the transplant setting is warranted.
INTRODUCTION
Hematopoietic cell transplant (HCT) offers a cure for many specific hematologic conditions and malignancies.
1 Although achievements in treatment approach and supportive care have resulted in substantial improvements in overall survival and treatment-related mortality, survivors of HCT remain at risk for significant late effects of therapy, including premature death. [2] [3] [4] [5] [6] [7] [8] A recent report from the Bone Marrow Transplant Survivor Study cohort reported that two-thirds of HCT survivors will develop a chronic health condition; in over one-third, the condition will be severe, life threatening, or fatal. 5 Cardiovascular disease is among the most life threatening of the potential late effects of HCT. Previous reports have described a range of HCT-related cardiotoxicity including valvular disease, pericardial effusion and pericarditis, hypertension, congestive heart failure and cardiac arrhythmias. 7, [9] [10] [11] [12] [13] Prior studies report that the incidence of arrhythmias during autologous or allogeneic HCT is 9-27%. [14] [15] [16] [17] [18] [19] With the increasing age of transplant recipients, the prevalence of pre-HCT comorbidities, including arrhythmia, is likely to increase. 8, 20, 21 To date, few studies have examined the impact of arrhythmias that occur after transplant, [21] [22] [23] although limited data suggest that supraventricular arrhythmias are associated with transplant-related mortality. 24 Furthermore, preexisting arrhythmias are included in calculations for the HCT-specific comorbidity index, which is used to risk stratify patients before transplant, but data on outcomes are limited. 25 Therefore, in an effort to better understand the impact of arrhythmia in the transplant setting, we conducted a single-center retrospective analysis of arrhythmia among patients undergoing HCT.
MATERIALS AND METHODS Participants
Data collection and analysis were performed with the approval of the Institutional Review Board of Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Protected health information was coded in accordance with the requirements of Health Insurance Portability and Accountability Act. Baseline demographic, clinical and laboratory data including history of preexisting arrhythmias, cardiovascular risk factors, cancer diagnosis and transplant characteristics were collected by a retrospective review of the inpatient and outpatient medical records of all patients who underwent autologous or allogeneic HCT between January 1999 and August 2009 at the Memorial Sloan-Kettering Cancer Center. Arrhythmia history and characteristics were confirmed by a cardiologist (WL Schaffer or RM Steingart). Clinically significant arrhythmia during transplant, as further defined below, was carefully noted. Records were also reviewed for length of hospital stay, intensive care unit (ICU) admission, in-hospital death, death at 1 year, and other clinical information. Because the pediatric and young adult population may differ with regard to treatment, risk factors, and outcomes after arrhythmia, only patients 40 years or older were included in the analysis. All care or screening was carried out on a clinical basis as indicated by the treating team. As such, all patients underwent a clinical assessment of cardiac function before transplant, including electrocardiogram and echocardiography or multiple gated cardiac blood pool imaging (MUGA). With few exceptions, patients had left ventricular ejection fraction of ⩾ 50% before transplantation. Stress tests were performed at the clinical discretion of the treating physician before transplantation.
Preparative regimens, donors and grafts
Regimens were identified as myeloablative, reduced intensity or nonmyeloablative as per previously described criteria. [26] [27] [28] TBI ⩽ 500 cGy was considered reduced intensity and ⩽ 200 cGy was considered non-myeloablative. Peripheral blood progenitor cell (PBPC) grafts for use in autologous HCT were generally obtained by administration of chemotherapy followed by granulocyte colony-stimulating factor with apheresis on the fifth and, if needed, the sixth day. Transplants primarily used PBPCs, but a small percentage of patients underwent bone marrow transplant. Donors for allogeneic HCT included matched/mismatched siblings or unrelated donors recruited via the National Marrow Donor Program. Slightly more than half of the grafts for allogeneic HCT were T-cell depleted. Selection of CD34+ stem cells from PBSC grafts was accomplished using the ISOLEX 300i Magnetic Cell Separator, followed by sheep RBC-rosette depletion of T cells as previously described. 29 Bone marrow T-cell depletion was accomplished by sequential soybean agglutination and sheep RBC-rosette depletion. 30 For T-cell-depleted grafts, no medicinal GvHD prophylaxis was given.
Arrhythmias and cardiac risk factors
Manual review of each medical chart, including physician's notes, electrocardiograms, Holter monitors, telemetry, echocardiography, MUGAs, and stress tests, was performed by a board-certified cardiologist (WS). Clinically significant arrhythmia was defined as paroxysmal or chronic atrial fibrillation, supraventricular tachycardia, ventricular tachycardia or fibrillation. Isolated ectopy, including ventricular premature contractions, atrial premature contractions and other clinically insignificant arrhythmias, such as those noted on telemetry and those that did not require a change in management, were not included in the definition of clinically significant. Major cardiovascular risk factors were identified, including essential hypertension, hypercholesterolemia, diabetes mellitus and past or present tobacco use.
Statistics
T-test (for continuous variables), Fisher's exact test (for categorical variables) and multivariable regression models were used to compare the length of hospital stay, ICU admission, in-hospital death and death at 1 year among patients with a history of arrhythmia before transplant (preexisting arrhythmia) with those without a history of arrhythmia. In addition, patients without preexisting arrhythmias who experienced new arrhythmia during transplant were compared with those who did not have arrhythmia at any time. Stepwise mutivariable logistic regression, testing age, gender, traditional cardiovascular risk factors (hypertension, hypercholesterolemia, smoking), diagnosis of diabetes mellitus, established (known) coronary artery disease, and transplant-related variables, was performed. P-values o 0.05 were considered significant. All statistical analyses were performed using STATA (Stata Corporation, College Station, TX, USA).
RESULTS

Overall
Eleven hundred seventy-seven patients underwent a total of 1255 HCTs: 446 (36%) allogeneic and 809 (64%) autologous (Table 1) . Patients were mostly male (60%), with a median age of 56 years (range, 40-76 years). Approximately one-third had a history of hypertension (404; 34%). The most common pretransplant diagnosis was lymphoma (427; 36%), followed by multiple myeloma (326; 28%) and leukemia (234; 20%). Forty-three patients were found to have arrhythmia documented before HCT; an additional 61 experienced an arrhythmia during transplant. The most common type of arrhythmia was atrial fibrillation (30, 49%), followed by supraventricular tachycardia (11, 18%) and atrial flutter (7, 11%). Only two patients (3%) experienced nonsustained ventricular tachycardia.
Patients with preexisting arrhythmias Among the patients who experienced arrhythmia before HCT (N = 43), atrial fibrillation was the most prevalent arrhythmia (32, 74%), followed by supraventricular tachycardia (3, 9%) and atrial flutter (2, 5%). One patient had a history of ventricular tachycardia. Patients with pre-HCT arrhythmias were older than those without (62 years old vs 56 years old, P o 0.001), but were equally distributed between males and females ( Table 2 ). Cancer diagnosis was not significantly different among patients with pre-HCT arrhythmias compared with those without. The incidence of cardiac risk factors, including smoking, hypertension, diabetes or hypercholesterolemia, was similar in those with pre-HCT arrhythmias as in those without, although patients with pre-HCT arrhythmias were slightly more likely to have established coronary artery disease (5% vs 1%, P = 0.06).
History of pre-HCT arrhythmia did not have an apparent impact on transplant parameters. As noted, transplants were predominantly performed with PBPC grafts (N = 1143) with no significant difference in grafts between patients with pre-HCT arrhythmias and those without (6% vs 97%, P = 0.4). Also, there was no significant difference between the two groups with respect to the type of transplant (autologous transplant, 55% vs 65%, P = 0.2) or the conditioning regimen (myeloablative, 75%, vs non-myeloablative or reduced intensity, 85%; P = 0.09). T-cell depletion was performed in approximately half of the allogeneic HCTs in both groups (50% vs 52%, P = 0.9), in keeping with standard practice patterns at this institution. Anti-thymocyte globulin (ATG) was administered in more than half of the allogeneic HCTs, with no significant difference between the patients with pre-HCT arrhythmia (60.0%) and those without (53%, P = 0.6).
Patients with pre-HCT arrhythmias were more likely to experience an arrhythmia during transplant, compared with patients without a history of arrhythmia (39% vs 5%, P o 0.001) ( Table 2) . Patients with pre-HCT arrhythmia were also more likely to be admitted to the ICU (23% vs 10%, P = 0.009) and had longer median hospital stays (26% vs 23 days, P = 0.04). Both in-hospital death and death within 1 year of transplant were also more frequent in patients with pre-HCT arrhythmias (23% vs 4% P = o 0.001 and 37% vs 16%, P o 0.001, respectively).
Arrhythmias during transplant Sixty-one patients (5%) experienced new arrhythmia during or following HCT, predominantly atrial fibrillation, atrial flutter or supraventricular tachycardias. Compared with patients who had no history of arrhythmia and did not experience arrhythmia during HCT (N = 1073), patients who experienced post-HCT arrhythmias were older (median age 56 vs 58 years, P = 0.023), but were not more likely to be male or to have known cardiovascular disease or risk factors (smoking, hypertension, diabetes, hypercholesterolemia, established coronary artery disease) ( Table 2) .
Patients undergoing bone marrow transplant were more likely to have post-HCT arrhythmia compared with patients undergoing PBPC transplants (16% vs 5%, P = 0.009), although the number of patients undergoing bone marrow transplant was small (N = 32). Arrhythmias were observed equally in patients receiving myeloablative vs reduced intensity or non-myeloablative HCTs combined (5% vs 7%, P = 0.4). Patients undergoing allogeneic HCTs (N = 738) were significantly more likely to experience post-HCT arrhythmias compared with patients receiving autologous (N = 396) HCTs (8% vs 4%, P = 0.001). Post-HCT arrhythmias occurred somewhat more often in T-cell-depleted (N = 218) compared with conventional HCTs (N = 916) (9% vs 4%; P = 0.01). In addition, there was a slightly higher incidence of post-HCT arrhythmias among patients receiving anti-thymocyte globulin (N = 214) as part of their treatment compared with patients who did not (N = 920) (9% vs 4%, P = 0.001).
Patients without a history of arrhythmia and who experienced an arrhythmia during HCT (N = 61) had poorer outcomes compared with patients who did not experience arrhythmia before or during transplant (N = 1073; Table 2 ). Patients with first arrhythmia following HCT, compared with those without any arrhythmia, were more likely to have an ICU admission (52% vs 7%, P o0.001), longer mean hospital stay (32 days vs 23, Po 0.001), increased in-hospital mortality (28% vs 3%, P o 0.001) and death within 1 year of transplantation (41% vs 15%, Po 0.001); ( Table 2) . Post-HCT arrhythmia was also associated with allogeneic, rather than autologous, stem cell transplant (odds error (OR) 3.5, 95% confidence interval (CI): 2.5, 4.8; P o0.001), whereas patients with a history of multiple myeloma had a slightly decreased risk for post-HCT arrhythmia (OR 0.4, 95% CI: 0.2, 0.9; P = 0.01).
In a multivariate model including age at transplant, diagnosis, pretransplant arrhythmia, receipt of anti-thymocyte globulin, receipt of T-cell-depleted stem cells, type of graft (bone marrow transplant vs PBPC) and type of transplant (allogeneic vs autologous), only allogeneic transplant (OR 4.3, 95% CI: 28, 6.6; Po 0.001) and post-HCT arrhythmia (OR 3.5, 95% CI: 2.1, 5.9; Po 0.001) retained an association with death at 1 year. When overall mortality during the study period was examined, post-HCT arrhythmia (OR 2.5, 95% CI: 1.5, 4.1; P o0.001), allogeneic transplant (OR 3.6, 95% CI: 2.4, 5.3; P o 0.001) and arrhythmia before transplant (OR 2.7, 95% CI: 1.4, 5.4; P = 0.003) were all found to be significant in a multivariate model including age, diagnosis, receipt of anti-thymocyte globulin, type of graft, and receipt of T-cell-depleted stem cells.
DISCUSSION
In this large single-center retrospective study, arrhythmias, whether occurring before HCT or first occurring after transplant, were associated with poor clinical outcomes, including longer hospital stay and increased mortality.
Patients with arrhythmia before transplant (pre-HCT arrhythmia) were more likely to experience an arrhythmia during transplant, compared with those who did not have an arrhythmia before transplant. Patients with pre-HCT arrhythmia were older and more frequently had preexisting coronary artery disease. 31 Importantly, although the most common pre-HCT arrhythmia was atrial fibrillation, a history of pre-HCT arrhythmia correlated with a twofold increase in the risk for ICU admission, a fivefold increase in the risk for in-hospital death and a twofold increase in the risk for death at 1 year. In sum, these findings suggest that pre-HCT arrhythmias, including atrial fibrillation, are of significant clinical importance.
Among patients with no history of arrhythmia, arrhythmias after HCT were a poor prognostic indicator. Patients with a new arrhythmia after transplant had an eightfold increase in the risk for ICU admission, a ninefold increase in the risk for in-hospital death and a threefold increase in the risk for death within 1 year of transplant. Notably, this single-center study found a lower prevalence of arrhythmias following transplant compared with prior reports, 20, 21, 32 possibly because of the relative youth of the patients in this analysis.
Arrhythmias were more common among patients who received bone marrow transplant, as compared with PBPC, and among those who received T-cell-depleted, compared with conventional grafts. To our knowledge, these observations have not been previously reported in the literature. Although some of these associations may be due to underlying illness not fully accounted for in the multivariate model, these associations could be further explored in a prospective setting.
Certain limitations to our findings should be noted. First and foremost, these results do not support an assertion that arrhythmia caused the observed adverse outcomes, and should be interpreted with that caveat. That said, only those arrhythmias that required a change in management or a treatment decision were highlighted for this study, and many patients were cared for without telemetry monitoring. This study, like others, is also limited by single-institution retrospective data, although this series is the largest reported to date. Single-institution medical records ensured that pretransplant records could be reviewed in a systematic and thorough manner, and chart details could be verified, when required. Finally, differences in electrolyte abnormalities, individual chemotherapy agents (such as melphalan), or receipt of calcineurin inhibitors were not included in this retrospective review; prospective studies may consider collecting these data for analysis.
With the limitations in mind, our findings continue to suggest that clinical attention to arrhythmias in the transplant setting is warranted. Atrial arrhythmias in the setting of transplantation may be similar to atrial arrhythmias in the post-operative setting, where the risks of increased length of stay, morbidity and mortality have been firmly established. [33] [34] [35] Since the recognition of atrial arrhythmias as a harbinger of poor outcomes in the surgical setting, a robust literature on early intervention and treatment algorithms has emerged, [33] [34] [35] although none exists for arrhythmia in the transplant setting. This gap in the literature opens the way for possible prophylactic, diagnostic and therapeutic interventions with respect to arrhythmias during transplantation. Furthermore, no prospective analysis has examined treatment algorithms for arrhythmia in the transplant setting. However, a paper from Fatema et al. 32 suggests that improved fluid management may be beneficial. Echocardiographic measures, including left atrial volume and diastolic parameters, may help identify patients without known arrhythmias who are at risk. 36 Evaluating brain natruretic peptide or more widespread use of telemetry monitoring may be helpful. 32 Finally, prophylaxis with agents such as amiodarone, and treatment with early cardioversion, or aggressive rate control may also offer benefit. 37, 38 In conclusion, in this analysis of 1178 patients undergoing HCT, a small but significant number of primarily supraventricular arrhythmias was noted. This manuscript is among the first to report that arrhythmia after transplant correlated strongly with adverse outcomes, including risks of ICU admission, in-hospital death and death within 1 year of transplant. Notably, causation cannot be concluded; it is unclear whether arrhythmias are simply markers of poorer outcomes in gravely ill patients or mechanistically contribute to the adverse outcomes. The small number of patients at each transplant center who experience arrhythmias will continue to limit our understanding and hamper development of diagnostic, prophylactic and treatment algorithms. Prospective, multicenter studies employing resources such as the Center for International Blood and Marrow Transplant Research (CIBMTR) are needed.
